Item request has been placed!
×
Item request cannot be made.
×
Processing Request
116P Angiopietin-2 (Ang-2) as a potential biomarker for guiding prescription of bevacizumab (bev) or anti-EGFR in RAS/BRAF wild-type (wt) unresectable metastatic colorectal cancer (mCRC): An exploratory analysis of the STRATEGIC-1 GERCOR-PRODIGE phase III trial
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Borg, C.1 (AUTHOR); Dourthe, L-M.2 (AUTHOR); André, T.3 (AUTHOR); Henriques, J.4 (AUTHOR); Bourgeois, V.5 (AUTHOR); Etienne, P-L.6 (AUTHOR); Desrame, J.7 (AUTHOR); Carola, E.8 (AUTHOR); Dupuis, O.9 (AUTHOR); Baba Hamed, N.10 (AUTHOR); Auby, D.11 (AUTHOR); Louvet, C.12 (AUTHOR); Maillard, E.13 (AUTHOR); Romano, O.14 (AUTHOR); Tournigand, C.15 (AUTHOR); Garcia Larnicol, M.L.16 (AUTHOR); Shacham Shmueli, E.17 (AUTHOR); Ghiringhelli, F.18 (AUTHOR); Degramont, A.19 (AUTHOR); Chibaudel, B.20 (AUTHOR)
- Source:
Annals of Oncology. 2024 Supplement 1, Vol. 35, pS54-S55. 2p.
- Subject Terms:
No Comments.